Your browser doesn't support javascript.
loading
Extracellular Vesicles from Mesenchymal Stem Cells: Towards Novel Therapeutic Strategies for Neurodegenerative Diseases.
Turano, Ermanna; Scambi, Ilaria; Virla, Federica; Bonetti, Bruno; Mariotti, Raffaella.
  • Turano E; Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Scambi I; Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Virla F; Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Bonetti B; Neurology Unit, Azienda Ospedaliera Universitaria Integrata Verona, 37124 Verona, Italy.
  • Mariotti R; Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Int J Mol Sci ; 24(3)2023 Feb 02.
Article en En | MEDLINE | ID: mdl-36769247
ABSTRACT
Neurodegenerative diseases are fatal disorders of the central nervous system (CNS) which currently lack effective treatments. The application of mesenchymal stem cells (MSCs) represents a new promising approach for treating these incurable disorders. Growing evidence suggest that the therapeutic effects of MSCs are due to the secretion of neurotrophic molecules through extracellular vesicles. The extracellular vesicles produced by MSCs (MSC-EVs) have valuable innate properties deriving from parental cells and could be exploited as cell-free treatments for many neurological diseases. In particular, thanks to their small size, they are able to overcome biological barriers and reach lesion sites inside the CNS. They have a considerable pharmacokinetic and safety profile, avoiding the critical issues related to the fate of cells following transplantation. This review discusses the therapeutic potential of MSC-EVs in the treatment of neurodegenerative diseases, focusing on the strategies to further enhance their beneficial effects such as tracking methods, bioengineering applications, with particular attention to intranasal delivery as a feasible strategy to deliver MSC-EVs directly to the CNS in an effective and minimally invasive way. Current progresses and limiting issues to the extent of the use of MSC-EVs treatment for human neurodegenerative diseases will be also revised.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Vesículas Extracelulares Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Vesículas Extracelulares Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article